Xiang Jiangdong, Zhou Lina, Li Shuangdi, Xi Xiaowei, Zhang Jiarong, Wang Yanqiu, Yang Yixia, Liu Xuelian, Wan Xiaoping
Shanghai First People's Hospital, Medical College, Shanghai Jiaotong University, Shanghai 200080, P.R. China.
Oncol Lett. 2012 Apr 1;3(4):865-870. doi: 10.3892/ol.2012.571. Epub 2012 Jan 16.
Special AT-rich sequence binding protein 1 (SATB1) is a master chromatin organizer that has recently been reported to directly upregulate metastasis-associated genes and downregulate tumor suppressor genes. However, its clinical significance in the case of ovarian cancer remains unclear. In the current study, we assessed the expression levels of SATB1 in ovarian cancer and aimed to show whether it may be a conventional clinicopathological parameter. Epithelial ovarian cancer (n=91), borderline cystadenoma (n=13) and normal ovarian background tissues (n=8) were collected immediately following excision during surgery. The mRNA expression levels of SATB1, VEGF-A and MMP-9 were determined using real-time quantitative PCR. Western blotting and immunohistochemical staining were carried out to detect the protein expression levels of SATB1. Expression levels within the ovarian cancer specimens were compared to the normal background tissues and analyzed against FIGO stage, lymph node involvement and histological type. SATB1 mRNA in malignant and borderline ovarian cystadenoma tissues was 6.74- and 5.70-fold higher compared with normal ovarian tissue, respectively (P<0.01). Western blot analysis revealed that a strong positive band of SATB1 expression was present in ovarian cancer tissues. Immunohistochemical staining showed that the positive expression rates of SATB1 in ovarian cancer, borderline ovarian cystadenoma and normal ovarian tissues were 69.2, 61.5 and 0% (P<0.01), respectively. SATB1 expression increased concomitantly with increasing FIGO stage and lymph node involvement. Survival curves showed that a higher SATB1 expression was correlated with shorter survival. Our results provide evidence that SATB1 expression is significantly associated with progression, metastasis and prognosis of epithelial ovarian cancer. SATB1 may therefore serve as a conventional clinicopathological parameter of ovarian cancer.
富含AT序列特异性结合蛋白1（SATB1）是一种主要的染色质组织者，最近有报道称它可直接上调转移相关基因并下调肿瘤抑制基因。然而，其在卵巢癌中的临床意义仍不明确。在本研究中，我们评估了SATB1在卵巢癌中的表达水平，旨在表明它是否可能是一个传统的临床病理参数。手术切除后立即收集上皮性卵巢癌组织（n = 91）、交界性囊腺瘤组织（n = 13）和正常卵巢背景组织（n = 8）。使用实时定量PCR测定SATB1、血管内皮生长因子A（VEGF-A）和基质金属蛋白酶-9（MMP-9）的mRNA表达水平。进行蛋白质免疫印迹和免疫组织化学染色以检测SATB1的蛋白表达水平。将卵巢癌标本中的表达水平与正常背景组织进行比较，并根据国际妇产科联盟（FIGO）分期、淋巴结受累情况和组织学类型进行分析。恶性和交界性卵巢囊腺瘤组织中的SATB1 mRNA分别比正常卵巢组织高6.74倍和5.70倍（P<0.01）。蛋白质免疫印迹分析显示卵巢癌组织中存在SATB1表达的强阳性条带。免疫组织化学染色显示，SATB1在卵巢癌、交界性卵巢囊腺瘤和正常卵巢组织中的阳性表达率分别为69.2%、61.5%和0%（P<0.01）。SATB1表达随FIGO分期和淋巴结受累情况的增加而升高。生存曲线显示，较高的SATB1表达与较短的生存期相关。我们的结果提供了证据，表明SATB1表达与上皮性卵巢癌的进展、转移和预后显著相关。因此，SATB1可能作为卵巢癌的一个传统临床病理参数。
